Cell biological factors associated with the response of breast cancer to systemic treatment.
暂无分享,去创建一个
[1] J. Coindre,et al. Expression of the GSTπ Gene and Response to Tamoxifen Therapy in Locally Advanced Breast Carcinomas a , 1993, Annals of the New York Academy of Sciences.
[2] J. Foekens,et al. Response to adjuvant chemotherapy in primary breast cancer: no correlation with expression of glutathione S-transferases. , 1993, British Journal of Cancer.
[3] J. Foekens,et al. Prognostic value of PS2 and cathepsin D in 710 human primary breast tumors: multivariate analysis. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] J. Foekens,et al. Critical review of growth factors as clinical tools in primary and metastatic breast cancer. , 1993, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.
[5] J. Foekens,et al. Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. , 1992, Cancer research.
[6] J. Foekens,et al. Ectopic expression of epidermal growth factor receptors induces hormone independence in ZR-75-1 human breast cancer cells. , 1992, Cancer research.
[7] E. Krenning,et al. Somatostatin receptor imaging in the diagnosis and treatment of neuroendocrine tumors , 1992, The Journal of Steroid Biochemistry and Molecular Biology.
[8] J. Foekens,et al. Clinical breast cancer, new developments in selection and endocrine treatment of patients , 1992, The Journal of Steroid Biochemistry and Molecular Biology.
[9] T. Pandita,et al. Resistance of human cervical carcinoma cells to tumor necrosis factor correlates with their increased sensitivity to cisplatin: evidence of a role for DNA repair and epidermal growth factor receptor. , 1992, Cancer research.
[10] J. Foekens,et al. Prognostic factors in human primary breast cancer: Comparison of c-myc and HER2/neu amplification , 1992, The Journal of Steroid Biochemistry and Molecular Biology.
[11] Umberto Veronesi,et al. Breast cancer (Third of three parts) , 1992 .
[12] W. McGuire,et al. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] B. Gusterson,et al. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] I. Andrulis,et al. The HER-2/neu oncogene in breast cancer: so what is new? , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] W. McGuire,et al. Response of human breast cancer cells to heat shock and chemotherapeutic drugs. , 1992, Cancer research.
[16] J. Sparano,et al. The potential role for biological therapy in the treatment of breast cancer. , 1992, Seminars in oncology.
[17] M. Lynch,et al. Changes in epidermal growth factor receptor expression and response to ligand associated with acquired tamoxifen resistance or oestrogen independence in the ZR-75-1 human breast cancer cell line. , 1992, British Journal of Cancer.
[18] C. Osborne,et al. HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] J. Foekens,et al. c-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer. , 1992, Cancer research.
[20] J. Foekens,et al. Sporadic amplification of the insulin-like growth factor 1 receptor gene in human breast tumors. , 1992, Cancer research.
[21] J. Foekens,et al. Prevalence of amplification of the oncogenes c-myc, HER2/neu, and int-2 in one thousand human breast tumours: correlation with steroid receptors. , 1992, European journal of cancer.
[22] J G Klijn,et al. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. , 1992, Endocrine reviews.
[23] J. Cairns,et al. Response to mitoxantrone in advanced breast cancer: correlation with expression of c-erbB-2 protein and glutathione S-transferases. , 1992, British Journal of Cancer.
[24] Mike Clarke,et al. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women , 1992 .
[25] A. D. Schryver,et al. Systemic treatment of early breast-cancer by hormonal, cytotoxic, or immune therapy: 133 randomized trials involving 31000 recurrences and 24000 deaths among 75000 women: 1 , 1992 .
[26] D. Hayes,et al. Immunocytochemical determination of the estrogen-regulated proteins Mr 24,000, Mr 52,000 and DF3 breast cancer associated antigen: clinical value in advanced breast cancer and correlation with estrogen receptor. , 1992, Annals of oncology : official journal of the European Society for Medical Oncology.
[27] K J Cullen,et al. Insulin-like growth factor-II overexpression in MCF-7 cells induces phenotypic changes associated with malignant progression. , 1992, Molecular endocrinology.
[28] A. Harris,et al. Mechanisms of multidrug resistance in cancer treatment. , 1992, Acta oncologica.
[29] H. Rochefort,et al. Cathepsin D in breast cancer: a tissue marker associated with metastasis. , 1992, European journal of cancer.
[30] R. Clarke,et al. Hormonal aspects of breast cancer. Growth factors, drugs and stromal interactions. , 1992, Critical reviews in oncology/hematology.
[31] S. Romain,et al. c-myc gene amplification in selected node-negative breast cancer patients correlates with high rate of early relapse. , 1992, European journal of cancer.
[32] K. Pritchard,et al. Adjuvant endocrine therapy of breast cancer. , 1992, Cancer treatment and research.
[33] V. Jordan,et al. Hormonal strategies for breast cancer: a new focus on the estrogen receptor as a therapeutic target. , 1992, Seminars in oncology.
[34] T. Visakorpi,et al. Association of C‐erbB‐2 protein over‐expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long‐term survival in breast cancer , 1991, International journal of cancer.
[35] R. Dickson,et al. Tissue culture conditions determine the effects of estrogen and growth factors on the anchorage independent growth of human breast cancer cell lines , 1991, The Journal of Steroid Biochemistry and Molecular Biology.
[36] B. Katzenellenbogen. Antiestrogen resistance: mechanisms by which breast cancer cells undermine the effectiveness of endocrine therapy. , 1991, Journal of the National Cancer Institute.
[37] C. Osborne,et al. Acquired tamoxifen resistance: correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen. , 1991, Journal of the National Cancer Institute.
[38] T. Kwok,et al. Epidermal growth factor reduces resistance to doxorubicin , 1991, International journal of cancer.
[39] M. Millward,et al. Epidermal growth factor receptors and doxorubicin plus ifosfamide/mesna in recurrent breast cancer , 1991, The Lancet.
[40] N. Piggott,et al. pNR-2/pS2 immunohistochemical staining in breast cancer: correlation with prognostic factors and endocrine response. , 1991, British Journal of Cancer.
[41] J. Bártková,et al. The relationship between c-erbB-2 expression, S-phase fraction and prognosis in breast cancer. , 1991, British Journal of Cancer.
[42] T. Perren. c-erbB-2 oncogene as a prognostic marker in breast cancer. , 1991, British Journal of Cancer.
[43] P. Chambon,et al. pS2 expression and response to hormonal therapy in patients with advanced breast cancer. , 1991, Cancer research.
[44] M. Fernö,et al. Association of INT2/HST1 coamplification in primary breast cancer with hormone-dependent phenotype and poor prognosis. , 1991, British Journal of Cancer.
[45] J. Foekens,et al. Growth factor-receptor pathway interfering treatment by somatostatin analogs and suramin: Preclinical and clinical studies , 1990, The Journal of Steroid Biochemistry and Molecular Biology.
[46] J. Bonneterre,et al. Insulin-like growth factor 1 receptors (IGF1-R) and IGF1 in human breast tumors , 1990, The Journal of Steroid Biochemistry and Molecular Biology.
[47] J. Klijn,et al. Assessment of estrogenic recruitment before chemotherapy in advanced breast cancer: Preliminary results of a double-blind randomized study of the eortic breast cancer cooperative group , 1990, Journal of Steroid Biochemistry and Molecular Biology.
[48] J. Foekens,et al. Prognostic value of pS2 protein and receptors for epidermal growth factor (EGF-R), Insulin-like growth factor-1 (IGF-1-R) and somatostatin (SS-R) in patients with breast and ovarian cancer , 1990, The Journal of Steroid Biochemistry and Molecular Biology.
[49] C. Osborne,et al. Regulation of breast cancer growth by insulin-like growth factors , 1990, The Journal of Steroid Biochemistry and Molecular Biology.
[50] A. Harris,et al. Epidermal growth factor receptor (EGFr) as a marker for poor prognosis in node-negative breast cancer patients: Neu and tamoxifen failure , 1990, The Journal of Steroid Biochemistry and Molecular Biology.
[51] C. Redmond,et al. Effect of tamoxifen on serum insulinlike growth factor I levels in stage I breast cancer patients. , 1990, Journal of the National Cancer Institute.
[52] R Beuscart,et al. Prognostic significance of insulin-like growth factor 1 receptors in human breast cancer. , 1990, Cancer research.
[53] J. Foekens,et al. Somatostatin receptor incidence and distribution in breast cancer using receptor autoradiography: Relationship to egf receptors , 1990, International journal of cancer.
[54] D. Slamon,et al. UCLA colloquium. New insights into breast cancer: the molecular biochemical and cellular biology of breast cancer. , 1990, Cancer research.
[55] J. Foekens,et al. Prediction of relapse and survival in breast cancer patients by pS2 protein status. , 1990, Cancer research.
[56] P. Rabbitts,et al. Non-P-glycoprotein-mediated multidrug resistance with reduced EGF receptor expression in a human large cell lung cancer cell line. , 1990, British Journal of Cancer.
[57] C. Redmond,et al. Endocrine treatment of breast cancer in women. , 1990, Endocrine reviews.
[58] W. Gullick. New developments in the molecular biology of breast cancer. , 1990, European journal of cancer.
[59] J. Klijn,et al. The clinical use of somatostatin analogues in the treatment of cancer. , 1990, Bailliere's clinical endocrinology and metabolism.
[60] A. Harris. Epidermal growth factor receptor: A marker of early relapse in breast cancer: Interactions with NEU , 1990 .
[61] J. Henry,et al. Expression of the oestrogen regulated pNR-2 mRNA in human breast cancer: relation to oestrogen receptor mRNA levels and response to tamoxifen therapy. , 1990, British Journal of Cancer.
[62] P. Darbre. 6. Steroids and steroid receptors in growth control of cultured breast cancer cells , 1990 .
[63] J. Foekens,et al. Prognostic Factors in Breast Cancer , 1990 .
[64] D. Merkel,et al. Prognostic factors in breast cancer. , 1992, The New England journal of medicine.
[65] J. Foekens,et al. Prognostic value of receptors for insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer. , 1989, Cancer research.
[66] J. Foekens,et al. Prognostic value of estrogen and progesterone receptors measured by enzyme immunoassays in human breast tumor cytosols. , 1989, Cancer research.
[67] J. Foekens,et al. Endocrine and antitumor effects of combined treatment with an antiprogestin and antiestrogen or luteinizing hormone-releasing hormone agonist in female rats bearing mammary tumors. , 1989, Endocrinology.
[68] R. Coombes,et al. Characterisation of a messenger RNA selectively expressed in human breast cancer. , 1989, British Journal of Cancer.
[69] J. Foekens,et al. Insulin‐like growth factor‐1 receptors and insulin‐like growth factor‐1‐like activity in human primary breast cancer , 1989, Cancer.
[70] S. Hirohashi,et al. Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene-coamplification units: hst-1/int-2 and c-erbB-2/ear-1. , 1989, Cancer research.
[71] J. Klijn,et al. Antiprogestins, a new form of endocrine therapy for human breast cancer. , 1989, Cancer research.
[72] R Clarke,et al. Progression of human breast cancer cells from hormone-dependent to hormone-independent growth both in vitro and in vivo. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[73] J. Devlin,et al. Effect of tamoxifen on plasma insulin-like growth factor I in patients with breast cancer. , 1989, Cancer research.
[74] C K Osborne,et al. Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An intergroup study. , 1989, The New England journal of medicine.
[75] E. Szabo,et al. Immunocytochemical analysis of estrogen receptors as a predictor of prognosis in breast cancer patients: comparison with quantitative biochemical methods. , 1989, Cancer research.
[76] J. Farndon,et al. EXPRESSION OF EPIDERMAL GROWTH FACTOR RECEPTORS ASSOCIATED WITH LACK OF RESPONSE TO ENDOCRINE THERAPY IN RECURRENT BREAST CANCER , 1989, The Lancet.
[77] A. Schally,et al. Characteristics and distribution of receptors for [d‐trp6]‐ luteinizing hormone‐releasing hormone, somatostatin, epidermal growth factor, and sex steroids in 500 biopsy samples of human breast cancer , 1989, Journal of clinical laboratory analysis.
[78] J. Bonneterre,et al. Insulin-like growth factor 1 receptors in human breast cancer and their relation to estradiol and progesterone receptors. , 1988, Cancer Research.
[79] V. Jordan,et al. Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. , 1988, Cancer research.
[80] J. Foekens,et al. Oestradiol enhances doxorubicin uptake and cytotoxicity in human breast cancer cells (MCF-7). , 1988, European journal of cancer & clinical oncology.
[81] E. Rutanen,et al. Receptors for epidermal growth factor and insulin-like growth factor I and their relation to steroid receptors in human breast cancer. , 1988, Cancer research.
[82] J. Klijn,et al. The prognostic value and relationships of patient characteristics, estrogen and progestin receptors, and site of relapse in primary breast cancer , 1988, Cancer.
[83] L. Rutqvist,et al. Response to tamoxifen and fluoxymesterone in a group of breast cancer patients with disease recurrence after cessation of adjuvant tamoxifen. , 1987, Cancer treatment reports.
[84] C. Osborne,et al. Alteration of EGF-receptor binding in human breast cancer cells by antineoplastic agents. , 1987, European journal of cancer & clinical oncology.
[85] R. Camplejohn,et al. Histological grade, elastosis, DNA ploidy and the response to chemotherapy of breast cancer. , 1987, British Journal of Cancer.
[86] J. Foekens,et al. Direct inhibitory effects of somatostatin (analogues) on the growth of human breast cancer cells. , 1987, Cancer research.
[87] A. Howell,et al. Endocrine therapy for advanced carcinoma of the breast: relationship between the effect of tamoxifen upon concentrations of progesterone receptor and subsequent response to treatment. , 1987, Cancer research.
[88] A. Howell,et al. MECHANISM OF ACTION OF ADJUVANT CHEMOTHERAPY IN EARLY BREAST CANCER , 1986, The Lancet.
[89] B. Spengler,et al. Epidermal growth factor receptor is increased in multidrug-resistant Chinese hamster and mouse tumor cells. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[90] J. Klijn,et al. Chemotherapy with estrogenic recruitment in breast cancer: experimental and clinical studies. , 1985 .
[91] K. Horwitz,et al. Progestin action and progesterone receptor structure in human breast cancer: a review. , 1985, Recent progress in hormone research.
[92] H. Portengen,et al. Estrogen, androgen, glucocorticoid, and progesterone receptors in progestin-induced regression of human breast cancer. , 1980, Cancer research.
[93] McGuire Wl,et al. Hormone receptors: their role in predicting prognosis and response to endocrine therapy. , 1978, Seminars in oncology.